<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">17082</article-id><article-id pub-id-type="doi">10.7554/eLife.17082</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Computational and Systems Biology</subject></subj-group></article-categories><title-group><article-title>5-hydroxymethylcytosine marks regions with reduced mutation frequency in human DNA</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-34388"><name><surname>Tomkova</surname><given-names>Marketa</given-names></name><aff><institution content-type="dept">Nuffield Department of Medicine</institution>, <institution>University of Oxford</institution>, <addr-line><named-content content-type="city">Oxford</named-content></addr-line>, <country>United Kingdom</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-57598"><name><surname>McClellan</surname><given-names>Michael</given-names></name><aff><institution content-type="dept">Ludwig Cancer Research Oxford</institution>, <institution>University of Oxford</institution>, <addr-line><named-content content-type="city">Oxford</named-content></addr-line>, <country>United Kingdom</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-12350"><name><surname>Kriaucionis</surname><given-names>Skirmantas</given-names></name><aff><institution content-type="dept">Ludwig Cancer Research Oxford</institution>, <institution>University of Oxford</institution>, <addr-line><named-content content-type="city">Oxford</named-content></addr-line>, <country>United Kingdom</country><email>skirmantas.kriaucionis@ludwig.ox.ac.uk</email></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-35991"><name><surname>Schuster-Boeckler</surname><given-names>Benjamin</given-names></name><aff><institution content-type="dept">Ludwig Cancer Research Oxford</institution>, <institution>University of Oxford</institution>, <addr-line><named-content content-type="city">Oxford</named-content></addr-line>, <country>United Kingdom</country><email>benjamin.schuster-boeckler@ludwig.ox.ac.uk</email></aff><xref ref-type="fn" rid="conf1"/></contrib></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-3046"><name><surname>Zilberman</surname><given-names>Daniel</given-names></name><role>Reviewing editor</role><aff><institution>University of California, Berkeley</institution>, <country>United States</country></aff></contrib></contrib-group><pub-date date-type="pub" publication-format="electronic"><day>16</day><month>05</month><year>2016</year></pub-date><elocation-id>e17082</elocation-id><supplementary-material><ext-link xlink:href="elife-17082-supp-v2.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material><history><date date-type="received"><day>20</day><month>04</month><year>2016</year></date><date date-type="accepted"><day>13</day><month>05</month><year>2016</year></date></history><permissions><copyright-statement>Â© 2016, Tomkova et al</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Tomkova et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><abstract><p>CpG dinucleotides are the main mutational hot-spot in most cancers. The characteristic elevated C&amp;gt;T mutation rate in CpG sites has been related to 5-methylcytosine (5mC), an epigenetically modified base which resides in CpGs and plays a role in transcription silencing. In brain nearly a third of 5mCs have recently been found to exist in the form of 5-hydroxymethylcytosine (5hmC), yet the effect of 5hmC on mutational processes is still poorly understood. Here we show that 5hmC is associated with an up to 53% decrease in the frequency of C&amp;gt;T mutations in a CpG context compared to 5mC. Tissue specific 5hmC patterns in brain, kidney and blood correlate with lower regional CpG&amp;gt;T mutation frequency in cancers originating in the respective tissues. Together our data reveal global and opposing effects of the two most common cytosine modifications on the frequency of cancer causing somatic mutations in different cell types.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group></article-meta></front><back><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group></back></article>